TY - JOUR
T1 - In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin
AU - Idelevich, Evgeny A.
AU - Von Eiff, Christof
AU - Friedrich, Alexander W.
AU - Iannelli, Domenico
AU - Xia, Guoqing
AU - Peters, Georg
AU - Peschel, Andreas
AU - Wanninger, Ingrid
AU - Becker, Karsten
PY - 2011/9
Y1 - 2011/9
N2 - Antistaphylococcal activity of the novel chimeric endolysin PRF-119 was evaluated with the microdilution method. The MIC50 and MIC90 of 398 methicillin-susceptible Staphylococcus aureus isolates were 0.098 μg/ml and 0.391 μg/ml, respectively (range, 0.024 to 0.780 μg/ml). Both the MIC50 and MIC90 values of 776 methicillin-resistant S. aureus isolates were 0.391 μg/ml (range, 0.024 to 1.563 μg/ml). All 192 clinical isolates of coagulase-negative staphylococci exhibited MIC values of >50 μg/ml. In conclusion, PRF-119 exhibited very good activity specifically against S. aureus. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
AB - Antistaphylococcal activity of the novel chimeric endolysin PRF-119 was evaluated with the microdilution method. The MIC50 and MIC90 of 398 methicillin-susceptible Staphylococcus aureus isolates were 0.098 μg/ml and 0.391 μg/ml, respectively (range, 0.024 to 0.780 μg/ml). Both the MIC50 and MIC90 values of 776 methicillin-resistant S. aureus isolates were 0.391 μg/ml (range, 0.024 to 1.563 μg/ml). All 192 clinical isolates of coagulase-negative staphylococci exhibited MIC values of >50 μg/ml. In conclusion, PRF-119 exhibited very good activity specifically against S. aureus. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
U2 - 10.1128/AAC.00217-11
DO - 10.1128/AAC.00217-11
M3 - Article
C2 - 21746950
SN - 0066-4804
VL - 55
SP - 4416
EP - 4419
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 9
ER -